AbbVie (ABBV) EBIAT (2012 - 2026)
AbbVie (ABBV) reported EBIAT of $697.0 million for Q1 2026, down 45.93% year-over-year from $1.3 billion in Q1 2025, and down 61.62% quarter-over-quarter from $1.8 billion in Q4 2025.
AbbVie (ABBV) EBIAT (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has 15 years of EBIAT data on file, last reported at $697.0 million in Q1 2026.
- EBIAT for Q1 2026 came in at $697.0 million, down 45.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.6 billion (down 13.43% YoY), and the FY2025 annual result was $4.2 billion, down 1.4% from the prior year.
- EBIAT slipped to $697.0 million in Q1 2026 per ABBV's latest filing, from $1.8 billion in the prior quarter.
- Over five years, EBIAT peaked at $4.5 billion in Q1 2022 and troughed at -$22.0 million in Q4 2024.
- A 5-year average of $1.5 billion and a median of $1.4 billion in 2024 frame the typical range for EBIAT.
- The sharpest annual moves came in 2024 and 2025: EBIAT sank 102.68% in 2024, then soared 8354.55% in 2025.
- A 5-year view of EBIAT shows it stood at $2.5 billion in 2022, then plunged by 66.76% to $822.0 million in 2023, then tumbled by 102.68% to -$22.0 million in 2024, then soared by 8354.55% to $1.8 billion in 2025, then sank by 61.62% to $697.0 million in 2026.
- Business Quant data shows ABBV's EBIAT at $697.0 million in Q1 2026, $1.8 billion in Q4 2025, and $186.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 2.48 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 7.40 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 5.24 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 697.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -4.24 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 2.71 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 2.68 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 697.00 Mn |
| Dec 31, 2025 | 1.82 Bn |
| Sep 30, 2025 | 186.00 Mn |
| Jun 30, 2025 | 938.00 Mn |
| Mar 31, 2025 | 1.29 Bn |
| Dec 31, 2024 | -22.00 Mn |
| Sep 30, 2024 | 1.56 Bn |
| Jun 30, 2024 | 1.37 Bn |
| Mar 31, 2024 | 1.37 Bn |
| Dec 31, 2023 | 822.00 Mn |
| Sep 30, 2023 | 1.78 Bn |
| Jun 30, 2023 | 2.02 Bn |
| Mar 31, 2023 | 241.00 Mn |
| Dec 31, 2022 | 2.47 Bn |
| Sep 30, 2022 | 3.95 Bn |
| Jun 30, 2022 | 924.00 Mn |
| Mar 31, 2022 | 4.49 Bn |
| Dec 31, 2021 | 4.04 Bn |
| Sep 30, 2021 | 3.18 Bn |
| Jun 30, 2021 | 766.00 Mn |